| Symbol | MBX |
|---|---|
| Name | MBX BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 12406 HORESHAM,STREET, CARMEL, Indiana, 46032, United States |
| Telephone | 3179893100 |
| Fax | — |
| — | |
| Website | https://www.mbxbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001776111 |
| Description | MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders. Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. We designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. Additional info from NASDAQ: |
New Form SCHEDULE 13G - MBX Biosciences, Inc. <b>Filed:</b> 2026-06-24 <b>AccNo:</b> 0001104659-26-077301 <b>Size:</b> 17 KB
Read more(90% Positive) MBX BIOSCIENCES, INC. (MBX) Announces Clinical Development Update
Read moreMBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
Read more📋 Bartram Richard (Ex-Officer) plans to sell 9K shares of MBX Biosciences, Inc. (at $30.55 each, total $280K) Filed: Jun 10, 2026 | ID: 004511
Read more📋 Bartram Richard (Ex-Officer) plans to sell 11K shares of MBX Biosciences, Inc. (at $29.66 each, total $321K) Filed: Jun 09, 2026 | ID: 004487
Read moreMathers Edward T 🟢 acquired 12.5K shares (1 derivative) of MBX Biosciences, Inc. (MBX) at $30.91 Transaction Date: Jun 04, 2026 | Filing ID: 259236
Read morePescovitz Ora H. 🟢 acquired 12.5K shares (1 derivative) of MBX Biosciences, Inc. (MBX) at $30.91 Transaction Date: Jun 04, 2026 | Filing ID: 258436
Read moreHeron Patrick J 🟢 acquired 12.5K shares (1 derivative) of MBX Biosciences, Inc. (MBX) at $30.91 Transaction Date: Jun 04, 2026 | Filing ID: 258435
Read moreStelzer Laurie 🟢 acquired 12.5K shares (1 derivative) of MBX Biosciences, Inc. (MBX) at $30.91 Transaction Date: Jun 04, 2026 | Filing ID: 258432
Read moreHoerter Steven L. 🟢 acquired 12.5K shares (1 derivative) of MBX Biosciences, Inc. (MBX) at $30.91 Transaction Date: Jun 04, 2026 | Filing ID: 258429
Read more